Structured evidence table for Urolithin A Muscle Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Urolithin A Muscle Health Randomized Trial | Background Urolithin A (UA), a gut microbiota-derived metabolite, has been proposed to improve skeletal muscle function, but evidence from randomized controlled trials has not been systematically summarized. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Health Randomized Trial | Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool, and the certainty of evidence for the primary quantitatively synthesized outcome was rated using the GRADE approach. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Health Randomized Trial | Conclusion The currently available randomized human evidence is limited to five small, short-term trials in clinically heterogeneous populations. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Health Randomized Trial | This systematic review and meta-analysis aimed to evaluate the effects of UA supplementation on muscle performance as well as biochemical and mitochondrial biomarkers in humans. | 2 | Dao T (2026) | Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials. |
| Urolithin A Muscle Health Randomized Trial | At 5 μM (RNA-seq), UA increased NOTCH1 (+73%), MYMX (+70%), PANX1 (+50%) and MSTN (+64%), and decreased FGF9 (-75%), ICAM5 (-52%) and MRLN (-33%), whereas UB decreased IGFN1 (-75%), TGFBI (-60%) and STC2 (-35%) and increased TGM2 (+59%). | 4 | Henrotin Y (2026) | Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes. |
| Urolithin A Muscle Health Randomized Trial | UA increased LIF (+80%) and decreased PTGS1 (-41%) and IL17B (-49%), whereas UB decreased PTGS1 (-43%) and increased IL17B (+45%). | 4 | Henrotin Y (2026) | Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes. |
| Urolithin A Muscle Health Randomized Trial | Both UA and UB reduced TGFBI protein levels dose-dependently (UA r 2 = 0.8582; UB r 2 = 0.7415). | 4 | Henrotin Y (2026) | Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes. |
| Urolithin A Muscle Health Randomized Trial | Background Urolithin A (UA) and urolithin B (UB) are gut microbiota-derived metabolites of ellagitannins reported to influence mitochondrial function, inflammation and muscle metabolism. | 4 | Henrotin Y (2026) | Exploring the Impact of Urolithins A and B on Muscle Health: A Transcriptomic Analysis in Human Myotubes. |
Source documents